Boston Scientific Slashes 2026 Outlook, Warns of Prolonged Headwinds
BSX is trading near its 52-week low of $42.2 (10% above the low).
Summary
Boston Scientific cut its 2026 adjusted EPS guidance to $3.28-$3.32 from $3.34-$3.41, below the $3.36 consensus, and lowered sales guidance to $21.178B-$21.379B from $21.479B-$21.78B. The company cited a sharp, unexpected slowdown in the U.S. Watchman heart implant market and competitive share losses in electrophysiology. Management warned these headwinds will persist into 2027, limiting EPS growth, with a meaningful recovery not expected until 2028. Q3 guidance also came in light: sales of $5.217B-$5.318B vs. $5.358B consensus and adjusted EPS of $0.80-$0.82 vs. $0.83 consensus. This follows a restructuring plan announced two days ago with $700M-$800M in charges. Shares fell 6.17% to $43.22, adding to recent pressure.
At the time of this announcement, BSX was trading at $46.63 on NYSE in the Life Sciences sector, with a market capitalization of approximately $69.3B. The 52-week trading range was $42.20 to $109.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.